Skip to content

Bacterial Protein Serves as Potential Groundbreaking Solution to Carbon Monoxide Poisoning

Scientists successfully developed a molecule capable of absorbing lethal carbon monoxide, avoiding hazardous side effects.

Bacterial Protein Emerges as Potential First True Counteragent for Carbon Monoxide Intoxication
Bacterial Protein Emerges as Potential First True Counteragent for Carbon Monoxide Intoxication

Bacterial Protein Serves as Potential Groundbreaking Solution to Carbon Monoxide Poisoning

In a groundbreaking development, a new protein-based antidote named RcoM-HBD-CCC has been engineered to combat carbon monoxide (CO) poisoning. This antidote, which acts like a molecular sponge, has shown promising results in preliminary tests.

The research group responsible for the development of RcoM-HBD-CCC, as published in the Proceedings of the National Academy of Sciences, has created a protein therapy that binds to CO nearly 50 times stronger than hemoglobin. This tight bond means that CO rarely escapes from the engineered protein, with a half-life inside the protein measured in days, compared to minutes for oxygen.

RcoM-HBD-CCC flushes harmlessly out of the body through urine, making it a potential lifesaver in cases of CO poisoning. In mice, RcoM-HBD-CCC has been shown to clear CO from the blood faster than untreated mice.

One of the key advantages of RcoM-HBD-CCC is that it seems to avoid binding to nitric oxide, a molecule that regulates blood pressure. This reduces the risk of hypertension and organ damage, a common and dangerous side effect of some CO antidotes.

The biggest potential of RcoM-HBD-CCC is as an actual antidote for CO poisoning. However, its potential uses extend beyond this. RcoM-HBD-CCC could help preserve organs before transplant, and might one day serve as a blood substitute for people with severe anemia or blood loss.

Despite these promising findings, many questions remain unanswered. The right dose, its effectiveness in severely poisoned patients, and how regulators will evaluate it are all areas that require further investigation. Human trials for the therapy are years away, and currently, the therapy using RcoM-HBD-CCC has only been tested in mice.

The statistics are alarming. Approximately 50,000 Americans visit emergency rooms each year due to CO exposure, and roughly 1,500 Americans die annually from CO exposure. If RcoM-HBD-CCC lives up to its promise, it could give doctors and first responders a tool that works in minutes, not hours.

The development of RcoM-HBD-CCC is inspired by a bacterial protein used by a bacterium to sense CO in its environment. The team behind this breakthrough believes that their discovery could revolutionise the treatment of CO poisoning, offering a safer and more effective solution for those at risk.

Read also: